Skip to Content

McKesson Corp MCK

Morningstar Rating
$551.56 −0.02 (< 0.01%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

McKesson Earnings: Strong End to 2024 With All Cylinders Firing, and 2025 Looks Even Stronger

Narrow-moat McKesson reported fourth-quarter earnings that came in higher than our expectations. Total sales of $76.4 billion were up 10.8% year over year as demand and the overall drug prescription trend remain stable and growing. Looking out to fiscal 2025, management provided a significantly better-than-expected guidance of 15%-17% revenue growth, driven by double-digit growth in both distribution and prescription technology solutions, and adjusted diluted EPS of $31.25 to $32.05 that roughly amounts to 14%-17% growth. After updating our near-term assumptions and baking in time value of money impacts, we raise our fair value estimate to $460 per share from $410.

Price vs Fair Value

MCK is trading at a 865% premium.
Price
$551.56
Fair Value
$848.00
Uncertainty
Medium
1-Star Price
$342.00
5-Star Price
$624.00
Economic Moat
Dyrbjm
Capital Allocation
Kqgmvvzj

Bulls Say, Bears Say

Bulls

McKesson distributes pharmaceutical products to nearly one third of the industry, leading to substantial negotiation leverage with generic drug manufacturers.

Bears

Reimbursement pressures on pharmacy and provider customers have led to an emphasis on cost containment, pressuring McKesson’s profitability.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MCK is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$551.58
Day Range
$548.73555.63
52-Week Range
$373.28566.01
Bid/Ask
$535.59 / $555.00
Market Cap
$71.69 Bil
Volume/Avg
539,621 / 672,305

Key Statistics

Price/Earnings (Normalized)
20.12
Price/Sales
0.24
Dividend Yield (Trailing)
0.44%
Dividend Yield (Forward)
0.45%
Total Yield
4.49%

Company Profile

McKesson Corp is one of three leading pharmaceutical wholesalers in the us engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the us pharmaceutical wholesale industry. Outside the us market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Sector
Healthcare
Industry
Medical Distribution
Stock Style Box
Large Core
Total Number of Employees
51,000

Competitors

Valuation

Metric
MCK
CVS
CAH
Price/Earnings (Normalized)
20.127.1313.57
Price/Book Value
0.95
Price/Sales
0.240.200.11
Price/Cash Flow
16.895.9010.07
Price/Earnings
MCK
CVS
CAH

Financial Strength

Metric
MCK
CVS
CAH
Quick Ratio
0.500.540.43
Current Ratio
0.920.810.98
Interest Coverage
15.574.5518.37
Quick Ratio
MCK
CVS
CAH

Profitability

Metric
MCK
CVS
CAH
Return on Assets (Normalized)
5.63%4.07%4.01%
Return on Equity (Normalized)
13.68%
Return on Invested Capital (Normalized)
64.13%7.90%97.71%
Return on Assets
MCK
CVS
CAH
See how this stock stacks up to its competitors with Morningstar Investor

Medical Distribution Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
COR
Cencora IncFrtlpjhzmBfzkfn$44.2 Bil
CAH
Cardinal Health IncTfyyntfyYffqkk$23.7 Bil
SHTDF
Sinopharm Group Co LtdFpbdd$9.0 Bil
SHTDY
Sinopharm Group Co Ltd ADRGqxmlj$9.0 Bil
SHPMF
Shanghai Pharmaceuticals Holding Co Ltd Class HLsl$8.6 Bil
SHPMY
Shanghai Pharmaceuticals Holding Co Ltd ADR repr Class HJshf$8.6 Bil
AMFPF
Amplifon SpA Az nom Post FrazionamentoLnxmv$8.4 Bil
MEPDF
Medipal Holdings CorpGjl$3.3 Bil
MAHLY
Medipal Holdings Corp ADRHxtg$3.0 Bil

Sponsor Center